Skip to content
← Full study record

NCT03330197 · MORE INFO

Limitations, agreements, and source contact

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG · Source last updated 2025-08-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
limitations And Caveats
description
Given the limited number of subjects enrolled and early closure of the study, complete assessment of safety and tolerability could not be determined. There was a wide range of adverse events reported and limited survival among the subjects enrolled.
point Of Contact
email
jholland@alaunos.com
organization
Alaunos Therapeutics
phone
650 273-2627
title
Jaymes Holland
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
limitations And Caveats
description
Given the limited number of subjects enrolled and early closure of the study, complete assessment of safety and tolerability could not be determined. There was a wide range of adverse events reported and limited survival among the subjects enrolled.
point Of Contact
email
jholland@alaunos.com
organization
Alaunos Therapeutics
phone
650 273-2627
title
Jaymes Holland

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice